The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
U.S. FDA approves ponatinib plus chemotherapy for adult patients with newly diagnosed Ph+ ALL
On March 19, 2024, it was announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to ponatinib, a BCR::ABL1 tyrosine kinase inhibitor, plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1,2 This approval is based on promising efficacy and safety outcomes from the III PhALLCON study (NCT03589326), which met its primary endpoint of minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.2
PhALLCON study
PhALLCON is a randomized, multicenter, open-label trial of ponatinib versus imatinib combined with low-intensity chemotherapy in adult patients with newly diagnosed Ph+ ALL. A total of 245 adult patients were randomized 2:1 to either ponatinib (n = 1,640) or imatinib (n = 81) arm. The key results were as follows1,2:
- A significantly higher improvement in MRD-negative CR rate at the end of induction for the ponatinib versus imatinib arm, at 30% and 12%, respectively (p = 0.0004).
- Similar safety profiles between the two arms, with no new safety signals reported.
- The most common adverse events were hepatic dysfunction, arthralgia, rash and related conditions, headache, pyrexia, abdominal pain, constipation, fatigue, nausea, oral mucositis, hypertension, pancreatitis/elevated lipase, peripheral neuropathy, hemorrhage, febrile neutropenia, fluid retention and edema, vomiting, paresthesia, and cardiac arrhythmias.
The U.S. FDA has recommended a dose of 30 mg ponatinib orally once daily, reduced to a dose of 15 mg orally once daily when an MRD-negative CR is achieved at the end of induction. Ponatinib should be continued with chemotherapy for up to 20 cycles until loss of response or unacceptable toxicity.
Conclusion
This approval marks an important clinical development, providing adult patients in the US with the first and only targeted frontline treatment for Ph+ ALL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content